



# COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

## DRUG UTILIZATION REVIEW PROGRAM

Virginia Medicaid Drug Utilization Review (DUR) Board  
Thursday, March 12, 2020, 1:00pm  
DMAS 7B Conference Room  
Agenda

1. **Call to Order and Introductions** – Chethan Bachireddy, MD, Chief Medical Officer, Chair
2. **Minutes** - Approval of Minutes from December 12, 2019 meeting
3. **RetroDUR Criteria Estimates**
4. **New Drugs - Grid**
  - a. Baqsimi™ Nasal Powder (glucagon)
  - b. Brukinsa™ (zanubrutinib)
  - c. Fasenra® Pen (benralizumab)
  - d. Gvoke™ Syringe (glucagon)
  - e. Oxbryta™ (voxelotor)
  - f. Pretomanid
  - g. Drug Updates: New Generics; New Dosage Form/ Strength/ Biosimilar; PDL-Eligible; Physician Administered Drugs
5. **Specialty Drugs**
  - a. Crizanlizumab IV
  - b. Semaglutide Oral
  - c. MRx Pipeline
6. **Topics for Discussion**
  - a. Concurrent Use of Opioids and Benzodiazepines
  - b. SUPPORT Act Update
  - c. DUR Quarterly Newsletter



# **COMMONWEALTH of VIRGINIA**

**Department of Medical Assistance Services**

## **DRUG UTILIZATION REVIEW PROGRAM**

- 7. Surveillance**
  - a. Opioid Use with Risk Factors and No Naloxone
  - b. Opioid Use with Risk Factors and Getting Naloxone
- 8. Reports**
  - a. ProDUR
  - b. RetroDUR
  - c. Utilization Analysis
- 9. Other Business**
- 10. Adjournment**

DRAFT